longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

00:18 ET Aphranel Launches "The Poetics of Time" Brand Strategy at IMCAS Paris, Redefining Long-Term Value in Medical Aesthetics

prnewswire
Feb 1, 2026 at 05:20 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Aphranel, a regenerative medical aesthetics brand, launched its global brand strategy "The Poetics of Time" at the 2026 IMCAS World Congress in Paris. This strategy emphasizes long-term aesthetic value over short-term results, focusing on sustainable beauty and patient confidence. The event featured discussions on integrating structure, individuality, and time in aesthetic practices, supported by clinical research. Aphranel also introduced the "The Poetics of Time Architect" Global Education Program to aid physicians in long-term aesthetic planning.

, /PRNewswire/ -- At the 2026 International Master Course on Aging Science (IMCAS) World Congress in Paris, Aphranel, a China-origin regenerative medical aesthetics brand specializing in CaHA injectables, under the company SHANGHAI MOYANG BIOTECHNOLOGY, unveiled its global brand strategy, "The Poetics of Time." The launch marked Aphranel's introduction of its long-term aesthetic philosophy to an international audience.

Continue Reading

Aphranel Launches “The Poetics of Time” Brand Strategy at IMCAS Paris

Held in a historic Parisian cinema, the event reflected Aphranel's intention to reframe how medical aesthetics considers time, shifting focus from short-term visual results to sustainable, long-term aesthetic value. The setting underscored Aphranel's belief that aesthetic decisions should be assessed not only by immediate outcomes, but by how they endure over time.

During the launch, Mr. Lin Guangming, Founder of Aphranel, addressed a recurring question in clinical practice:
"People often ask how long an aesthetic result can 'last.' Behind this question lies a deeper concern — whether today's decision will still feel right in the future. What we consistently hear from real-world clinical feedback is not only a desire for performance, but a need for long-term confidence."

This perspective forms the foundation of Aphranel's "The Poetics of Time" philosophy, which views beauty not as a race against aging, but as a thoughtful collaboration with time and a long-term relationship worth investing in.

Within this framework, Aphranel defines aesthetic value through three dimensions. Immediate Efficacy emphasizes reliable structural support and visible initial improvement, enabled by Aphranel's high-G' CaHA material. Evolving Vitality reflects Aphranel's ability to stimulate continuous collagen regeneration, allowing results to develop naturally. Assured Metabolism highlights Aphranel's commitment to fully controllable biodegradation, supporting confident long-term treatment planning for physicians and patients.

Alongside the brand strategy launch, Aphranel introduced the "The Poetics of Time Architect" Global Education Program, designed to support physicians in technical execution and long-term aesthetic planning tailored to individual patients. Aphranel believes that professional value lies in integrating structure, individuality, and time.

The launch also featured cross-disciplinary dialogue among experts from medicine, business, and culture, examining how long-term aesthetic thinking extends beyond clinical practice. Scientific presentations reinforced that Aphranel's philosophy is grounded in verifiable clinical research and material science. Concluding the event, Mr. Lin noted that just as cinema invites reflection beyond the present moment, Aphranel seeks to translate an understanding of time into lasting confidence and composure.

Be With Time. Be Like Me.

SOURCE SHANGHAI MOYANG BIOTECHNOLOGY CO., LTD

Login to unlock3,005characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Apr 22, 2026 at 10:30 AMInnovative Drug Revenue Share Surpasses 60% for First Time, HENGRUI PHARMA Q1 Revenue Hits 8.14 Billion Yuan, Net Profit…
  • Apr 20, 2026 at 06:34 PMEli Lilly Announces $7 Billion Acquisition of Kelonia: Pioneering the 'In Vivo CAR-T' Frontier and Leading Gene Therapy …
  • Apr 16, 2026 at 11:12 AMUS Stocks Hit New Highs, Retail Investors Miss Out en masse: Tom Lee Says Next Rally Will Be Led by Them
  • Apr 7, 2026 at 10:32 PMReminder: Key events to watch intraday (all times Beijing Time)
  • Apr 7, 2026 at 03:50 PMGoldman Sachs Issues Rare Call: "Generational Buying Opportunity" for US Tech Stocks Has Quietly Begun

Related Stocks

ALPS Medical Breakthrough

ALPS Medical Breakthrough

USSBIO

Invesco Biotechnology & Genome ETF

Invesco Biotechnology & Genome ETF

USPBE

iShares Biotechnology ETF

iShares Biotechnology ETF

USIBB

LongbridgeAI